Ardelyx, Inc. (ARDX)
3.735
-0.16
(-3.98%)
USD |
NASDAQ |
Aug 24, 16:00
3.76
+0.02
(+0.67%)
After-Hours: 20:00
Ardelyx Enterprise Value : 943.54M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 943.54M |
| August 20, 2026 | 946.03M |
| August 19, 2026 | 978.42M |
| August 18, 2026 | 951.02M |
| August 17, 2026 | 985.90M |
| August 14, 2026 | 985.90M |
| August 13, 2026 | 948.53M |
| August 12, 2026 | 963.47M |
| August 11, 2026 | 956.00M |
| August 10, 2026 | 970.95M |
| August 07, 2026 | 970.95M |
| August 06, 2026 | 1.188B |
| August 05, 2026 | 1.198B |
| August 04, 2026 | 1.223B |
| August 03, 2026 | 1.215B |
| July 31, 2026 | 1.208B |
| July 30, 2026 | 1.230B |
| July 29, 2026 | 1.220B |
| July 28, 2026 | 1.241B |
| July 27, 2026 | 1.235B |
| July 24, 2026 | 1.228B |
| July 23, 2026 | 1.252B |
| July 22, 2026 | 1.240B |
| July 21, 2026 | 1.243B |
| July 20, 2026 | 1.243B |
| Date | Value |
|---|---|
| July 17, 2026 | 1.270B |
| July 16, 2026 | 1.251B |
| July 15, 2026 | 1.295B |
| July 14, 2026 | 1.260B |
| July 13, 2026 | 1.255B |
| July 10, 2026 | 1.290B |
| July 09, 2026 | 1.315B |
| July 08, 2026 | 1.327B |
| July 07, 2026 | 1.315B |
| July 06, 2026 | 1.305B |
| July 02, 2026 | 1.287B |
| July 01, 2026 | 1.260B |
| June 30, 2026 | 1.245B |
| June 29, 2026 | 1.262B |
| June 26, 2026 | 1.341B |
| June 25, 2026 | 1.467B |
| June 24, 2026 | 1.499B |
| June 23, 2026 | 1.496B |
| June 22, 2026 | 1.543B |
| June 18, 2026 | 1.464B |
| June 17, 2026 | 1.413B |
| June 16, 2026 | 1.371B |
| June 15, 2026 | 1.374B |
| June 12, 2026 | 1.375B |
| June 11, 2026 | 1.400B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| REGENXBIO, Inc. | 725.36M |
| ACADIA Pharmaceuticals, Inc. | 4.195B |
| Alnylam Pharmaceuticals, Inc. | 31.27B |
| Anika Therapeutics, Inc. | 278.32M |
| Savara, Inc. | 1.006B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.72M |
| Revenue (Quarterly) | 120.88M |
| Total Expenses (Quarterly) | 137.60M |
| EPS Diluted (Quarterly) | -0.0674 |
| Gross Profit Margin (Quarterly) | 94.74% |
| Profit Margin (Quarterly) | -13.83% |
| Earnings Yield | -6.05% |
| Normalized Earnings Yield | -6.051 |